Fucoidan and novel coronavirus (COVID-19)
Marinova continues to field queries from researchers working to advance potential vaccines and treatments for novel coronavirus (COVID-19).
Marinova recognises the vital work of the World Health Organisation and Centre for Disease Control and Prevention. As the world continues to combat the global spread of the novel coronavirus (COVID-19), it is essential that all guidelines and advice issued by health authorities are adhered to.
Marinova has previously investigated the effect of Maritech® fucoidan on coronaviruses and noted little activity in comparison to the extent observed with other viruses such as influenza, herpes, human metapneumovirus and respiratory syncytial virus. It is also important to note that no investigation has occurred in relation to Maritech® fucoidan and the novel coronavirus (COVID-19). It is for these reasons it is not possible to recommend fucoidan as a coronavirus blocking agent.
As progress towards a vaccine continues, Marinova will continue to focus its active research and development program on the immunomodulatory properties of fucoidan. Extensive evidence supports a range of potential beneficial effects including boosted immune response, activation of Natural Killer cells and cytotoxic T cells, the mobilization of stem cells and the dampening of allergic responses. A summary of the evidence for Maritech® fucoidan as a immune support agent can be found here.